Discovery of lixisenatide analogues as long-acting hypoglycemic agents using novel peptide half-life extension technology based on mycophenolic acid.

As expected, the albumin affinity of 2a ( k ′ = ∼13.3) was higher than that of lixisenatide and 1f, for 2b–2d with OEG spacers, there is a clear trend that with increasing length of the OEG spacer, the compounds display an increased affinity to albumin binding relative to 2a (2b, k ′ = ∼14.1; 2c, k ′ = ∼15.2; 2d, k ′ = ∼17.2).

also in 19,460 other papers